Links to articles on the study:
medpagetoday.comLink to medpagetoday.commedpagetoday.com
healthmanagement.orgBiologic Ventricular Assist Tissue in Heart FailureA new article reports interim findings from the BioVAT-HF phase 1–2 clinical trial, which investigated a novel regenerative treatment for advanced heart…healthmanagement.org
Link to full study:
Paper · N Engl J Med · 2026Stem-Cell-Derived Biologic Ventricular Assist Tissue in Heart Failure.Conclusion: In this interim analysis, cardiac remuscularization with BioVAT was associated with an increase in the target heart-wall thickness, left ventricular ejection fraction, and KCCQ-OSS at 3 months; all the patients had at least one adverse event. Longer-term follow-up and further clinical investigation are warranted. (Funded by the German Center for Cardiovascular Research and Repairon; BioVAT-HF ClinicalTriapubmed.ncbi.nlm.nih.gov
